Muhammad UmairMushtaqMD

Oncology • Kansas City, KS

Hematologic Oncology

Associate Professor, Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center

Join to view full profile

Dr. Mushtaq is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mushtaq's full profile

Already have an account?

Office
3901 Rainbow Blvd
Kansas City, KS 66160
Phone+1 913-945-5793

Summary

Clinical investigator and physician with a focus on Hematologic Malignancies, Bone Marrow Transplant, Cellular Therapy, Immunotherapy, and Global Health

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2017 - 2020
Cook County Health and Hospitals SystemResidency, Internal Medicine, 2014 - 2017
Allama Iqbal Medical CollegeClass of 2010, MBBS

Certifications & Licensure

MO State Medical License 2021 - 2026
KS State Medical License 2020 - 2025
WI State Medical License 2017 - 2023
IL State Medical License 2014 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Karl and Irene Eisemann Award for Hematologic Malignancies and Cellular Therapeutics University of Kansas Medical Center, 2023
Clinical Research Excellence Award University of Kansas Medical Center, 2023
Robert Korngold Award for the Best Clinical Science in Cellular Therapy article American Society for Transplantation and Cellular Therapy, 2021

Clinical Trials

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant Start of enrollment: 2023 Dec 11
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) Start of enrollment: 2023 Apr 06
Terminated
Phase 1
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide Start of enrollment: 2020 Jan 31
Recruiting
Phase 1
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS Start of enrollment: 2021 Dec 16
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2023 Dec 21
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Efficacy of Ruxolitinib with corticosteroids in idiopathic pneumonia syndrome post-allogeneic hematopoietic stem cell transplantation: A single-center experience and s...
Moazzam Shahzad, Muhammad Atif Khan, Muhammad Kashif Amin, Zouina Sarfraz, Fizza Zulfiqar
Transplant Immunology. 2024-12-01
Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma.
Barry Paul, Faiz Anwer, Shahzad Raza, Aytaj Mammadzadeh, Bayan Khasawneh
Cancers. 2024-08-23
Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation.
Moazzam Shahzad, Muhammad Kashif Amin, Polina Bellman, Joe Al-Ramahi, Jawad Noor
Transfusion. 2024-08-01

Abstracts/Posters

The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023
Atallah R, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S375-S376, 2/2024
The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally
Atallah R, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S373-S374, 2/2024
The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
Khaliq A, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S208, 2/2024
Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure
Lutfi F, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S229, 2/2024
BCMA Re-Emergence: Can It Serve As a Prognostic Biomarker in Multiple Myeloma after CAR-T?
Rashid A, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S194-S195, 2/2024
Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy
Soomro MA, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S373, 2/2024
Chimeric Antigen Receptor T-Cell (CAR-T) Access Among Rural and Health Professional Shortage Area (HPSA) Populations in the Midwest
Tabak C, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S323, 2/2024
VD-PACE As Salvage and Bridging Therapy to Transplant and Cellular Therapy in Triple Class Relapsed/Refractory Multiple Myeloma
Venkatesh P, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S389-S390, 2/2024
A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients
Wesson W, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S207-S208, 2/2024
Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
Amin MK … Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S241-42, 2/2024
Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Ce...
Shahzad M … Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S172, 2/2024
Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myelo...
Shah N, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S225-S226, 2/2024
BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma
Rashid A, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6801, 12/2023
Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma
Wesson W, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6914, 12/2023
Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians
Atallah R, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6678, 12/2023
Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple Myeloma
Venkatesh P, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6694, 12/2023
Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure
Lutfi F, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6916, 12/2023
Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy
Soomro MA, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6900, 12/2023
Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation
Al-Ramahi J … Mushtaq MU, Blood. 2023; 142 (S1): 7028, 12/2023
The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally
Atallah R, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 3327, 12/2023
Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics
Snyder J, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 1985, 12/2023
Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant
Mammadzadeh A, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 4727, 12/2023
The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
Khaliq A, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 2344, 12/2023
Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
Amin M … Mushtaq MU, Blood. 2023; 142 (S1): 2242, 12/2023
Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Ce...
Shahzad M … Mushtaq MU, Blood. 2023; 142 (S1): 3523, 12/2023
Join now to see all

Lectures

Highlights of American Society of Hematology Annual Meeting 2023. University of Kansas Cancer Center ASH Review
Kansas City, KS - 1/2024
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients. Grand Rounds Speaker at the University of Kansas Me...
Kansas City, KS - 4/2022
Graft failure and graft rejection. American Society of Transplantation & Cellular Therapy Fall Clinical Education Conference (ASTCT CEC)
Virtual - 9/2021
Highlights of American Society of Hematology Annual Meeting 2020. University of Kansas Cancer Center ASH Review
Kansas City, KS - 1/2021
Highlights of American Society of Hematology Annual Meeting 2019. University of Wisconsin Carbone Cancer Center Grand Rounds
Madison, WI - 1/2020
Matrix-based biomarkers for cancer immunotherapy. Guest Speaker at University of Kansas, Kansas City, KS (08/2019), University of Arizona, Tucson, AZ (08/2019), Wake F...
8/2019
Highlights of American Society of Hematology Annual Meeting 2018. University of Wisconsin Carbone Cancer Center Grand Rounds
Madison, WI - 2/2019
Join now to see all

Research History

Principal InvestigatorUniversity of Kansas Cancer Center, Kansas City, KS2020 - Present
Co-InvestigatorUniversity of Wisconsin Carbone Cancer Center, Madison, WI2017 - 2020
Co-InvestigatorCook County Health & Hospitals System, Chicago, IL2014 - 2017
Post-Doc Research AssociateColumbia University Irving Medical Center, New York, NY2013 - 2014
Principal InvestigatorPunjab Department of Health/Allama Iqbal Medical College, Lahore, Pakistan2008 - 2012
Research AssociateNew York City Department of Health and Mental Hygiene, New York, NY2010 - 2011

Professional Memberships

American College of Physicians - ACP
Member
American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member
American Society for Transplantation and Cellular Therapy - ASTCT
Member
Blood & Marrow Transplant Clinical Trials Network - BMT CTN
Member
Society for Immunotherapy of Cancer - SITC
Member

Other Languages

Hindi, Urdu, Punjabi

External Links

LinkedInhttps://www.linkedin.com/in/mumushtaq/
Google Scholarhttps://scholar.google.com/citations?hl=en&user=CzpYfMYAAAAJ
My Bibliography (NIH)https://www.ncbi.nlm.nih.gov/myncbi/1TKnUcnWu6tQn-/bibliography/public/